NASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis $31.77 -0.75 (-2.31%) Closing price 04:00 PM EasternExtended Trading$31.76 0.00 (-0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immunovant Stock (NASDAQ:IMVT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunovant alerts:Sign Up Key Stats Today's Range$31.61▼$32.7750-Day Range$26.73▼$37.6652-Week Range$21.86▼$45.42Volume702,864 shsAverage Volume1.50 million shsMarket Capitalization$6.57 billionP/E RatioN/ADividend YieldN/APrice Target$44.60Consensus RatingModerate Buy Company Overview Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders. Its medicines are investigational and are not approved for commercial use. Immunovant was launched by Roivant Sciences in 2018 and remains part of the Roivant group. The company is led by President and Chief Executive Officer Peter Salzmann.AI Generated. May Contain Errors. Read More Immunovant Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreIMVT MarketRank™: 2.24671412924 of 5 starsImmunovant scored higher than 45% of companies evaluated by MarketBeat, and ranked 560th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingImmunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialImmunovant has a consensus price target of $44.60, representing about 39.4% upside from its current price of $32.00.Amount of Analyst CoverageImmunovant has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunovant's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($2.49) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -12.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -12.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 10.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.15% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 15.26, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 1.51%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentImmunovant has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Immunovant this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $895,852.00 in company stock.Percentage Held by Insiders1.90% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMVT Stock News HeadlinesImmunovant Stock Gets Higher EPS Forecast from HC WainwrightNovember 20 at 2:12 AM | americanbankingnews.comImmunovant (NASDAQ:IMVT) Upgraded to "Hold" at Wall Street ZenNovember 14, 2026 | americanbankingnews.comEarn $4,500 a month? Your income may count for moreEarn $4,500 or more a month? Pennie lets you explore personal loan options that consider your income, not just your credit score. Options include personal loans up to $250,000 and APRs starting at 5.99%. Checking your rate is free, and the soft credit check won't affect your score. Pennie is a loan marketplace, not a lender. Offers come from third-party partners and are not guaranteed.November 20 at 1:00 AM | Pennie Financial (Ad)Immunovant (NASDAQ:IMVT) Director Atul Pande Sells 3,000 Shares of Company StockNovember 13, 2026 | insidertrades.comImmunovant (NASDAQ:IMVT) Stock Price Expected to Rise, Truist Financial Analyst SaysNovember 12, 2026 | americanbankingnews.comImmunovant (IMVT) Q2 2027 Earnings Call TranscriptNovember 9, 2026 | finance.yahoo.comImmunovant, Inc. (IMVT) Q2 2027 Earnings Call TranscriptNovember 9, 2026 | seekingalpha.comImmunovant, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026November 9, 2026 | marketscreener.comMSee More Headlines IMVT Stock Analysis - Frequently Asked Questions How have IMVT shares performed this year? Immunovant's stock was trading at $25.42 at the start of the year. Since then, IMVT stock has increased by 25.9% and is now trading at $31.9950. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) announced its earnings results on Monday, November, 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.27. Read the conference call transcript. Who are Immunovant's major shareholders? Immunovant's top institutional shareholders include Two Seas Capital LP (2.23%), State Street Corp (2.03%), Baker BROS. Advisors LP (1.34%) and Goldman Sachs Group Inc. (0.77%). Insiders that own company stock include Sciences Ltd Roivant, Peter Salzmann, Julia G Butchko, Eva Renee Barnett, William L Macias, Mark S Levine, Eric Venker, Tiago Girao, Michael Geffner, Melanie Gloria, Jay S Stout, Tuyl Christopher Van, Douglas J Hughes, Atul Pande, Andrew J Fromkin and Robert Graham Susman. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Micron Technology (MU), Grifols (GRFS), Li Auto (LI), Palantir Technologies (PLTR) and Plug Power (PLUG). Company Calendar Last Earnings11/09/2026Today11/20/2026Investor Day 202612/09/2026Next Earnings (Estimated)2/05/2027Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, IMVT's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMVT CIK1764013 Webwww.immunovant.com Phone(917) 410-3120FaxN/AEmployees315Year Founded2018Price Target and Rating Average Price Target for Immunovant$44.60 High Price Target$62.00 Low Price Target$28.00 Potential Upside/Downside+40.4%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$505.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.01% Return on Assets-56.19% Debt Debt-to-Equity RatioN/A Current Ratio7.31 Quick Ratio7.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.17 per share Price / Book10.02Miscellaneous Outstanding Shares206,950,000Free Float203,016,000Market Cap$6.57 billion OptionableOptionable Beta0.95 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:IMVT) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.